Jazz Pharmaceuticals (JAZZN) Income Statement
Jazz Pharmaceuticals Income Statement
Last quarter (Q2 2026), Jazz Pharmaceuticals's total revenue was $1.21B, an increase of 15.55% from the same quarter last year. In Q2, Jazz Pharmaceuticals's net income was $192.80M. See Jazz Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 4.27B | $ 4.07B | $ 3.83B | $ 3.66B | $ 3.09B | |
| $ 3.76B | $ 3.62B | $ 3.40B | $ 3.12B | $ 2.65B | |
| $ 3.54B | $ 2.91B | $ 2.82B | $ 3.18B | $ 2.48B | |
| Depreciation and Amortization | $ 696.30M | $ 660.07M | $ 638.70M | $ 629.47M | $ 552.48M |
| $ 262.76M | $ 1.52B | $ 1.45B | $ 1.47B | $ 1.03B | |
| $ 224.42M | $ 716.63M | $ 578.58M | $ -65.53M | $ 170.28M | |
| $ -853.01M | $ -247.94M | $ -283.66M | $ -317.18M | $ -283.83M | |
| $ -628.59M | $ 468.69M | $ 294.92M | $ -382.70M | $ -113.55M | |
| $ -356.15M | $ 560.12M | $ 414.83M | $ -224.06M | $ -328.95M | |
| Per Share Metrics | |||||
| Basic EPS | $ -5.84 | $ 9.06 | $ 6.55 | $ -3.58 | $ -5.51 |
| Diluted EPS | $ -5.84 | $ 8.65 | $ 6.10 | $ -3.58 | $ -5.51 |
| Weighted Average Shares Outstanding | 60.98M | 61.84M | 63.29M | 62.54M | 59.69M |
| Weighted Average Shares Outstanding (Diluted) | 60.98M | 66.01M | 72.07M | 62.54M | 59.69M |
Currency in USD
